Loading…
Pharmacology and clinical use of a new group of antiarrhythmic drugs: Derivatives of tricyclic nitrogen-containing systems
This paper is concerned with a new group of antiarrhythmic drugs: derivatives of phenothiazine and dibenzazepine which belong to tricyclic nitrogen-containing systems. It has been discovered that the transition from ω-aminoalkyl to ω-aminoacyl phenothiazine derivatives results in a decrease in psych...
Saved in:
| Published in: | Pharmacological research 1992-04, Vol.25 (3), p.217-225 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13 |
| container_end_page | 225 |
| container_issue | 3 |
| container_start_page | 217 |
| container_title | Pharmacological research |
| container_volume | 25 |
| creator | Kaverina, Natalia V. Sokolov, Sergei F. |
| description | This paper is concerned with a new group of antiarrhythmic drugs: derivatives of phenothiazine and dibenzazepine which belong to tricyclic nitrogen-containing systems. It has been discovered that the transition from
ω-aminoalkyl to
ω-aminoacyl phenothiazine derivatives results in a decrease in psychotropic activity and an increase in cardiovascular, particularly antiarrhythmic, action. Based on structural and antiarrhythmic activity studies, the new and effective drugs ethmozine, ethacizine and bonnecor have been selected and extensively studied. Data on spectra and mechanisms of their action, obtained in different arrhythmia models, have been confirmed by clinical studies. Correlation between pharmacological properties and electrophysiological mechanisms, and differences in action of the drugs studied on brain and heart plasma membrane receptors may serve as a starting point for the further directed search for new antiarrhythmic drugs among tricyclic nitrogen-containing structures. |
| doi_str_mv | 10.1016/S1043-6618(05)80070-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73167399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043661805800702</els_id><sourcerecordid>73167399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13</originalsourceid><addsrcrecordid>eNqFkF2L1TAQhoMo67r6ExZyIaIX1clpkibeLLJ-woKCeh3SdNoTaZNjkh6pv96eD_TSq0yYZ94ZHkKuGbxkwOSrrwx4XUnJ1HMQLxRAA9XmHrlkoGXFmJL3D_UZeUge5fwDADRncEEumGCqkeKS_P6ytWmyLo5xWKgNHXWjD97Zkc4ZaeyppQF_0SHFeXf8huJtStulbCfvaJfmIb-mbzH5vS1-j_kAleTdsgY5GnxJccBQuRiKXZPDQPOSC075MXnQ2zHjk_N7Rb6_f_ft9mN19_nDp9s3d5WrlS5VjYKjhFqjYG0rhWuxa7V1DhTrrFbQblCBtrwXSqlWN0zqDtE1vG-UcKy-Is9OubsUf86Yi5l8djiONmCcs2lqJpta6xUUJ9ClmHPC3uySn2xaDANzcG6Ozs1BqAFhjs7NZp27Pi-Y2wm7f1MnyWv_6blv8yq2TzY4n_9inANXnK_YzQnDVcbeYzLZeQwOO5_QFdNF_59D_gCaQaBh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73167399</pqid></control><display><type>article</type><title>Pharmacology and clinical use of a new group of antiarrhythmic drugs: Derivatives of tricyclic nitrogen-containing systems</title><source>ScienceDirect Journals</source><creator>Kaverina, Natalia V. ; Sokolov, Sergei F.</creator><creatorcontrib>Kaverina, Natalia V. ; Sokolov, Sergei F.</creatorcontrib><description>This paper is concerned with a new group of antiarrhythmic drugs: derivatives of phenothiazine and dibenzazepine which belong to tricyclic nitrogen-containing systems. It has been discovered that the transition from
ω-aminoalkyl to
ω-aminoacyl phenothiazine derivatives results in a decrease in psychotropic activity and an increase in cardiovascular, particularly antiarrhythmic, action. Based on structural and antiarrhythmic activity studies, the new and effective drugs ethmozine, ethacizine and bonnecor have been selected and extensively studied. Data on spectra and mechanisms of their action, obtained in different arrhythmia models, have been confirmed by clinical studies. Correlation between pharmacological properties and electrophysiological mechanisms, and differences in action of the drugs studied on brain and heart plasma membrane receptors may serve as a starting point for the further directed search for new antiarrhythmic drugs among tricyclic nitrogen-containing structures.</description><identifier>ISSN: 1043-6618</identifier><identifier>EISSN: 1096-1186</identifier><identifier>DOI: 10.1016/S1043-6618(05)80070-2</identifier><identifier>PMID: 1518765</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Animals ; Anti-Arrhythmia Agents - chemistry ; Anti-Arrhythmia Agents - pharmacology ; Anti-Arrhythmia Agents - therapeutic use ; Antiarythmic agents ; arrhythmias ; Arrhythmias, Cardiac - drug therapy ; Biological and medical sciences ; bonnecor ; Brain - drug effects ; Cardiovascular system ; Cell Membrane - drug effects ; Dibenzazepines - chemistry ; Dibenzazepines - pharmacology ; Dibenzazepines - therapeutic use ; ethacizine ; ethmozine ; Hemodynamics - drug effects ; Medical sciences ; Moricizine - chemistry ; Moricizine - pharmacology ; Moricizine - therapeutic use ; Pharmacology. Drug treatments ; Phenothiazines - chemistry ; Phenothiazines - pharmacology ; Phenothiazines - therapeutic use ; supraventricular ; ventricular</subject><ispartof>Pharmacological research, 1992-04, Vol.25 (3), p.217-225</ispartof><rights>1992 The Italian Pharmacological Society</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13</citedby><cites>FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1043661805800702$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4404844$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1518765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaverina, Natalia V.</creatorcontrib><creatorcontrib>Sokolov, Sergei F.</creatorcontrib><title>Pharmacology and clinical use of a new group of antiarrhythmic drugs: Derivatives of tricyclic nitrogen-containing systems</title><title>Pharmacological research</title><addtitle>Pharmacol Res</addtitle><description>This paper is concerned with a new group of antiarrhythmic drugs: derivatives of phenothiazine and dibenzazepine which belong to tricyclic nitrogen-containing systems. It has been discovered that the transition from
ω-aminoalkyl to
ω-aminoacyl phenothiazine derivatives results in a decrease in psychotropic activity and an increase in cardiovascular, particularly antiarrhythmic, action. Based on structural and antiarrhythmic activity studies, the new and effective drugs ethmozine, ethacizine and bonnecor have been selected and extensively studied. Data on spectra and mechanisms of their action, obtained in different arrhythmia models, have been confirmed by clinical studies. Correlation between pharmacological properties and electrophysiological mechanisms, and differences in action of the drugs studied on brain and heart plasma membrane receptors may serve as a starting point for the further directed search for new antiarrhythmic drugs among tricyclic nitrogen-containing structures.</description><subject>Animals</subject><subject>Anti-Arrhythmia Agents - chemistry</subject><subject>Anti-Arrhythmia Agents - pharmacology</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Antiarythmic agents</subject><subject>arrhythmias</subject><subject>Arrhythmias, Cardiac - drug therapy</subject><subject>Biological and medical sciences</subject><subject>bonnecor</subject><subject>Brain - drug effects</subject><subject>Cardiovascular system</subject><subject>Cell Membrane - drug effects</subject><subject>Dibenzazepines - chemistry</subject><subject>Dibenzazepines - pharmacology</subject><subject>Dibenzazepines - therapeutic use</subject><subject>ethacizine</subject><subject>ethmozine</subject><subject>Hemodynamics - drug effects</subject><subject>Medical sciences</subject><subject>Moricizine - chemistry</subject><subject>Moricizine - pharmacology</subject><subject>Moricizine - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenothiazines - chemistry</subject><subject>Phenothiazines - pharmacology</subject><subject>Phenothiazines - therapeutic use</subject><subject>supraventricular</subject><subject>ventricular</subject><issn>1043-6618</issn><issn>1096-1186</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNqFkF2L1TAQhoMo67r6ExZyIaIX1clpkibeLLJ-woKCeh3SdNoTaZNjkh6pv96eD_TSq0yYZ94ZHkKuGbxkwOSrrwx4XUnJ1HMQLxRAA9XmHrlkoGXFmJL3D_UZeUge5fwDADRncEEumGCqkeKS_P6ytWmyLo5xWKgNHXWjD97Zkc4ZaeyppQF_0SHFeXf8huJtStulbCfvaJfmIb-mbzH5vS1-j_kAleTdsgY5GnxJccBQuRiKXZPDQPOSC075MXnQ2zHjk_N7Rb6_f_ft9mN19_nDp9s3d5WrlS5VjYKjhFqjYG0rhWuxa7V1DhTrrFbQblCBtrwXSqlWN0zqDtE1vG-UcKy-Is9OubsUf86Yi5l8djiONmCcs2lqJpta6xUUJ9ClmHPC3uySn2xaDANzcG6Ozs1BqAFhjs7NZp27Pi-Y2wm7f1MnyWv_6blv8yq2TzY4n_9inANXnK_YzQnDVcbeYzLZeQwOO5_QFdNF_59D_gCaQaBh</recordid><startdate>19920401</startdate><enddate>19920401</enddate><creator>Kaverina, Natalia V.</creator><creator>Sokolov, Sergei F.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920401</creationdate><title>Pharmacology and clinical use of a new group of antiarrhythmic drugs: Derivatives of tricyclic nitrogen-containing systems</title><author>Kaverina, Natalia V. ; Sokolov, Sergei F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Anti-Arrhythmia Agents - chemistry</topic><topic>Anti-Arrhythmia Agents - pharmacology</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Antiarythmic agents</topic><topic>arrhythmias</topic><topic>Arrhythmias, Cardiac - drug therapy</topic><topic>Biological and medical sciences</topic><topic>bonnecor</topic><topic>Brain - drug effects</topic><topic>Cardiovascular system</topic><topic>Cell Membrane - drug effects</topic><topic>Dibenzazepines - chemistry</topic><topic>Dibenzazepines - pharmacology</topic><topic>Dibenzazepines - therapeutic use</topic><topic>ethacizine</topic><topic>ethmozine</topic><topic>Hemodynamics - drug effects</topic><topic>Medical sciences</topic><topic>Moricizine - chemistry</topic><topic>Moricizine - pharmacology</topic><topic>Moricizine - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenothiazines - chemistry</topic><topic>Phenothiazines - pharmacology</topic><topic>Phenothiazines - therapeutic use</topic><topic>supraventricular</topic><topic>ventricular</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaverina, Natalia V.</creatorcontrib><creatorcontrib>Sokolov, Sergei F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaverina, Natalia V.</au><au>Sokolov, Sergei F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacology and clinical use of a new group of antiarrhythmic drugs: Derivatives of tricyclic nitrogen-containing systems</atitle><jtitle>Pharmacological research</jtitle><addtitle>Pharmacol Res</addtitle><date>1992-04-01</date><risdate>1992</risdate><volume>25</volume><issue>3</issue><spage>217</spage><epage>225</epage><pages>217-225</pages><issn>1043-6618</issn><eissn>1096-1186</eissn><abstract>This paper is concerned with a new group of antiarrhythmic drugs: derivatives of phenothiazine and dibenzazepine which belong to tricyclic nitrogen-containing systems. It has been discovered that the transition from
ω-aminoalkyl to
ω-aminoacyl phenothiazine derivatives results in a decrease in psychotropic activity and an increase in cardiovascular, particularly antiarrhythmic, action. Based on structural and antiarrhythmic activity studies, the new and effective drugs ethmozine, ethacizine and bonnecor have been selected and extensively studied. Data on spectra and mechanisms of their action, obtained in different arrhythmia models, have been confirmed by clinical studies. Correlation between pharmacological properties and electrophysiological mechanisms, and differences in action of the drugs studied on brain and heart plasma membrane receptors may serve as a starting point for the further directed search for new antiarrhythmic drugs among tricyclic nitrogen-containing structures.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>1518765</pmid><doi>10.1016/S1043-6618(05)80070-2</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-6618 |
| ispartof | Pharmacological research, 1992-04, Vol.25 (3), p.217-225 |
| issn | 1043-6618 1096-1186 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73167399 |
| source | ScienceDirect Journals |
| subjects | Animals Anti-Arrhythmia Agents - chemistry Anti-Arrhythmia Agents - pharmacology Anti-Arrhythmia Agents - therapeutic use Antiarythmic agents arrhythmias Arrhythmias, Cardiac - drug therapy Biological and medical sciences bonnecor Brain - drug effects Cardiovascular system Cell Membrane - drug effects Dibenzazepines - chemistry Dibenzazepines - pharmacology Dibenzazepines - therapeutic use ethacizine ethmozine Hemodynamics - drug effects Medical sciences Moricizine - chemistry Moricizine - pharmacology Moricizine - therapeutic use Pharmacology. Drug treatments Phenothiazines - chemistry Phenothiazines - pharmacology Phenothiazines - therapeutic use supraventricular ventricular |
| title | Pharmacology and clinical use of a new group of antiarrhythmic drugs: Derivatives of tricyclic nitrogen-containing systems |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A23%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacology%20and%20clinical%20use%20of%20a%20new%20group%20of%20antiarrhythmic%20drugs:%20Derivatives%20of%20tricyclic%20nitrogen-containing%20systems&rft.jtitle=Pharmacological%20research&rft.au=Kaverina,%20Natalia%20V.&rft.date=1992-04-01&rft.volume=25&rft.issue=3&rft.spage=217&rft.epage=225&rft.pages=217-225&rft.issn=1043-6618&rft.eissn=1096-1186&rft_id=info:doi/10.1016/S1043-6618(05)80070-2&rft_dat=%3Cproquest_cross%3E73167399%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-3e54e6039e51bb65cbedb9acc081da980b2e809a4f5888b97169deec74f785c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73167399&rft_id=info:pmid/1518765&rfr_iscdi=true |